

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2021
FOR
JOINING JACK**

NR Barton
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The trustees present their report with the financial statements of the charity for the year ended 30 April 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives and activities

Objectives and activities for the public benefit

The principal objective of the charity is to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure of the condition.

Significant activities

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley.

Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and director of research with Duchenne UK.

Research

Our research strategy has six elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step. But on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1) Fund and accelerate research for early stage clinical trials

Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.

2) Facilitate and accelerate research

We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.

3) Implementation of the Standards of Care (SoC) in the UK

The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We have launched a new project DMD Care UK to tackle this issue. The project will ensure everyone in the UK living with Duchenne has access to the best care.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

4) Work alongside industry

We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.

5) Continued engagement with regulators and policy makers

We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.

6) Collaborate with families and charities globally

We work with families to empower them to get the best access to care and treatments for their children. As a result of COVID-19 we could not hold our free patient information days. We decided to work with Duchenne UK to hold 14 free patient information webinars that have been watched by 300 people. Alex Johnson sits on the board of the World Duchenne Organization to ensure we collaborate with charities internationally.

Our shared Scientific Advisory Board with Duchenne UK is

Professor Dame Kay Davies
Dr Mike Gait
Professor Annemeike Aartsma-Rus
Dr Tony Hall
Dr Eric Hoffman
Dr Bob McDonald
Alastair Robertson

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of the three main flagship fundraising multi-participant events.

An existing database of more than 100 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish.

Although in smaller numbers due to COVID measures, our volunteers have continued to do this when events returned in the second half of 2021.

Achievement and performance

Fundraising activities

Run Wigan Festival 2020

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 and, after the disappointment of the 2018 Half Marathon cancellation due to weather conditions and runner safety, and a fall in registered runners for the Main Race, a fourth distance was introduced to the event in the shape of a 10 Miler. The race was a sell-out.

The 4th Run Wigan Festival was due to take place on March 22, 2020, once again under the title sponsorship of HW Moon Toyota Wigan but with less than a week to go, the event was postponed at the start of the first National Lockdown. After first being rescheduled to take place alongside the Wigan 10k in September 2020, a second postponement was later confirmed until 2021. The event was eventually cancelled due to the ongoing restrictions and a third national Lockdown. The 2020 event was staged virtually with runners offered the chance to take part virtually and have their medals posted out or defer their place to 2021. We had a fantastic response with 1,500 runners taking part virtually and the event managed to raise just over £28,000.

The 2021 event was eventually cancelled due to the ongoing restrictions and a third national Lockdown. Given the likelihood that no mass participation events would take place until at least the second quarter of 2021, we made the decision to stage another Virtual Event - The Joining Jack 13 for 13.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The Joining Jack 13 for 13

This was announced in January 2021 with runners invited to complete a virtual half marathon - 13.1 miles either on the official race route or a route/route of their choice throughout March. It was open to all ages to keep the event inclusive and for all Team JJ supporters to mark the 13th birthday of the charity's inspiration Jack Johnson in January 2021.

Runners submitted their evidence via email and received a bespoke medal. With extensive coverage across our social media channels and a concentrated marketing campaign to our Run Wigan Festival database, the event raised £6,500.

The date has been set for the return of the Run Wigan Festival in 2022 on Sunday, March 20, and registration is open.

*PLEASE NOTE 329 runners have deferred places in the 2022 event, and all runners from the virtual event were offered a 25% discount to sign up as a gesture of goodwill by the charity for their support and to maintain interaction with our established event network. This will have a major effect on fundraising from the event but it will be the final event to be affected financially by postponements and the fallout from COVID and lockdowns.

Wigan Bike Ride 2020

After three years of taking part as a team in organised Bike Rides, the charity made the decision to stage its first ever organised bike ride. This took place on July 22nd 2017 under the Title Sponsorship of Develop UK and featured a 50 Mile main ride on open roads through Wigan and Lancashire, and a 5 Mile family ride on closed roads along the Wigan 10k route. It was an unprecedented success and on Sunday, June 30, 2019, the charity staged the third Wigan Bike Ride and raised a record-breaking total.

The Bike Ride has now raised more than £95,000 and the date for the 4th event was set for July 5, 2020 but was cancelled due to the ongoing pandemic. The 4th Wigan Bike Ride did take place as a virtual event with 278 riders participating with support from all over the north-west and UK and from across the world including Australia, America, Chile and the UAE. Riders completed their 50 miles and were sent a Joining Jack JJ the Duchenne Destroyer medal and special edition Virtual Wigan Bike Ride T-shirt. The event raised more than £10,000.

Some light at the end of the tunnel saw the charity plan its first mass participation flagship event with the return of the 5th Wigan Bike Ride on Saturday, July 10, 2021. A change of venue due to availability and slightly smaller numbers (just under 300), saw the event take place just before COVID guidelines were fully relaxed so social distancing was maintained outdoors. New Hardcore and Highway routes were introduced for the 50 mile ride with £17,000 raised - we have now raised over £120,000 from the Bike Ride as a flagship event.

*PLEASE NOTE: As a gesture of goodwill, the remaining 51 riders who had registered to take part in 2020 before the decision to stage virtually was announced, and went on to complete the Virtual Ride, were offered a 50% discount to sign up in 2021. Along with smaller numbers, this did have an effect on fundraising.

The date has now been set for the 6th Wigan Bike Ride on Sunday, June 19, 2022 and registration is open.

JOINING JACK
REPORT OF THE TRUSTEES
FOR THE YEAR ENDED 30 APRIL 2021

Wigan 10k 2020

On September 1st 2019, we completed our 7th Wigan 10k under a new title sponsor Williams BMW Bolton. First launched in 2013 as Joining Jack's FIRST flagship fundraising event, the race was another amazing day for the charity. More than 2,800 runners registered for the 10k and 500 for the Family Mile with more than £35,000 raised from runners' registration fees, sponsorship of the event, race registration fees, donations and merchandise sold. This was a slight fall on previous years with the added costs of a new title sponsor's branding adding to outgoings. When approached to continue the Title sponsorship, Williams BMW declined and the event was temporarily left without a main sponsor.

The 2020 Wigan 10k was earmarked for Sunday September 6. This was temporarily brought forward to Saturday, September 5th when the decision was taken to reschedule the Run Wigan Festival due to COVID-19, to run alongside the event over a complete weekend. The event would be sponsored by HW Moon Toyota Wigan as part of the sponsorship deal of the Run Wigan Festival.

However, with restrictions still in place surrounding mass participation events, the decision was taken to stage the 2020 8th Wigan 10k virtually. Runners were offered the option to defer their place to 2021 or take part in the virtual run - to be completed throughout September and October, and receive a bespoke Wigan 10k medal. Registration for virtual entries was reopened and a total of 537 runners completed the virtual run. The event raised £11,000 - again significantly down on previous years but still a profit in uncertain times.

The 9th Wigan 10k, featuring a 10k, 5k and Family Mile took place on Sunday, September 6th with almost 2,500 runners taking part. (NB, the 5k was rescheduled to take place on the Sunday after originally being planned for the Saturday evening.)

The event raised £21,000 and also saw the 20,000th runner cross the finish line since the event was launched in 2013. Numbers were a little disappointing but not unexpected and nevertheless encouraging as the events and fundraising industry continues to recover from COVID.

The date for next year's 10th Wigan 10 has been set for Sunday, September 11, 2022.

*PLEASE NOTE: The 268 runners who had registered to take part in 2020 before the decision to stage virtually was announced, were offered a 50% discount to sign up for 2021 as a gesture of goodwill.

Emirates Dubai Sevens

The 2020 event was cancelled due to the global pandemic.

The charity did look to take part in the 2021 and paid an agreed 20% of the registrations fees but, with concerns over players being able to travel from other countries, an enquiry was made into switching to the Over 45s category which could accommodate UK-based players who are more known to the Johnson family. However, this proved impractical as the category already had the allotted number of entries.

Alex, Andy and the Trustees will discuss entry into the 2022 early next year.

Yorkshire Three Peaks, Supporter Fundraising & Community Fundraising events

The biggest ever JY3 Peaks had been planned for Saturday, September 6, 2020. This was also cancelled due to the global pandemic. The date has been set for the return of the JY3P 2022 - the Joining Jack Yorkshire Three Peaks challenge - which will take place on Saturday, May 7. Recruitment will begin early in the New Year.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Other events and fundraising

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This has had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2021 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022

The virtual 13 for 13 event and the return of both the Wigan Bike Ride and Wigan 10k, has raised home-based events have raised a combined £44,500 and there have been other smaller contributions from supporters and donors throughout the year.

The Emirates Dubai Sevens has previously raised £90,000 - £100,000 which has meant a significant reduction in fundraising for both 2020 and 2021.

Other fundraising initiatives 2021

The Joining Jack team have been working on a Team JJ merchandise campaign through the charity's eBay shop and also a Team JJ advent calendar to build awareness.

The charity has also had continued support from sponsors, event partners and supporters throughout the continued restrictions and limited fundraising opportunities, maintaining a strong connection with the Team JJ brand and continuing to raise awareness of our overall charitable objective.

Achievement and performance

This year's advocacy activities

We continued to represent the Duchenne community by speaking at virtually at international patient conferences around the world, workshops and meetings with the FDA, EMA, MHRA, NICE and at the Houses of Parliament.

Ensuring the best care for all patients - DMD Care UK. It is our mission that every child with Duchenne - wherever they live in the UK - should be able to access the same quality of care, and that that level of care should be excellent. We don't want people to "make do", we want them to shine.

We have brought together the DMD community of patients and families with neuromuscular experts, and specialist clinicians to try to make this a reality with our DMD Care UK project.

"DMD Care UK is such an important project for raising and harmonising standards of care for ALL people in the UK living with DMD. It works because we are a collaboration between neuromuscular expert centres, specialist clinicians and the patient community - we are all working towards the same goal!" Dr Michela Guglieri, John Walton Muscular Dystrophy Research Centre in Newcastle; PI of DMD Care UK

We have been carrying out a comprehensive review to get a benchmark of how five areas are managed across the country.

- Psychosocial
- Bone and Endocrine Health
- Cardiac Health
- Respiratory Health
- Physiotherapy
- Emergency Care

Next year we will begin work on the other 5 areas of care we have identified as priorities.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Update on Psychosocial Care:

This year one of our key focuses has been psychosocial care, looking at the mental health of people with DMD and their families. We are partnering with the Duchenne Research Fund to look at research into psychosocial care and research. We want every patient and their family members to receive the appropriate psychosocial evaluation, care and treatment throughout their lives.

Update on Bone and Endocrine health:

The Endocrine system is a network of glands in the body which make the hormones that help us all function. We are working with the British Society of Paediatric Endocrinology and Diabetes to find an effective way to monitor the health of the endocrine system, and also bone health. Steroids have a noticeable effect on these areas so we are producing guidance for families and health professionals.

One particularly challenging area is delayed puberty so we have produced leaflets specifically on this subject giving help and advice.

We have also produced detailed advice on steroid stress dosing - when extra steroids are need for patients who become ill or injured. We are working on updating checklists in clinics across the country to educate parents and medical staff about this. We've also produced a wristband to be worn by people on steroids so that medical staff in Accident and Emergency departments are alerted and know that they need special treatment. So far 340 bracelets have been ordered by families.

Educating parents is key so this year we held a webinar on steroid stress dosing. This was well attended.

Update on Emergency Care:

We are also developing an emergency care app, which is currently in the testing phase.

Update on Cardiac Health:

We have developed new recommendations due to be published in Q1 2022.

Achievement and performance

Update on Respiratory Health:

We have developed new recommendations due to be published in Q1 2022.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The DMD Hub - expending access to clinical trials:

We are so proud of the pioneering work of the DMD Hub. We want to make it possible for any family to take part in clinical trials if they want to, allowing them to access treatments they wouldn't otherwise receive.

In 2015, when we created the concept of the DMD Hub there just weren't the facilities to make this happen. Each year, we extend our outposts and staff to make this a reality. Thanks to the DMD Hub, 300 more boys have been recruited onto clinical trials so far. 11 Hospitals are now running 10 trials into potential treatments for DMD.

We have extended the contract for the DMD Hub Manager, Emma Heslop, for another four years. She is the vital contact point between clinicians, industry partners and patients. She helps select sites and recruit patients and makes sure best practice is shared between Hub sites.

We have expanded the DMD Hub team to look at improving the recruitment of patients to trials, and the training of Hub staff to prepare for more gene therapy trials in the UK.

Through our seed funding the DMD Hub has been able to fund five new posts across the different Hub sites, employing people like research nurses and physiotherapists to help run clinical trials.

The DMD Hub is collaborating on an international patient preference project with PPMD and RTI International. This project will assess and explore clinician, patient, and caregiver attitudes, priorities, and risk tolerance regarding gene therapy as a potential treatment option for Duchenne muscular dystrophy. With gene therapies entering human studies, this is a critical time to understand the treatment preference of people affected by Duchenne. These technologies offer great promise to be disease modifying but come with risks and burden.

We have funded new gene therapy work to overcome immunological challenges that prevent gene therapy being available to be used to treat all patients.

First Patient dosed with gene therapy through DMD Hub network. We are planning a workshop

Partnership with Whizz Kidz and PPL to build the dream chair:

Williams Advanced Engineering, the technology spin off of Williams F1, have joined forces with Duchenne UK and Whizz-Kidz to input on the design of our dream wheelchair.

We made powerful links across the Duchenne Community: parents, scientists, clinicians and Governments to identify and fund the best treatments worldwide for Duchenne through our leadership and sponsorship of Treat NMD, a global network of scientists and clinicians.

Alex continues to sit on the board of the World Duchenne Organization (WDO) that has helped to organize international awareness events like World Duchenne Awareness Day and provides support to charities around the world.

We have continued to provide vital support to families during COVID. We have hosted educational webinars and held our first in person patient conference since the pandemic began in October in Manchester.

Alex has continued to provide support to families through telephone calls.

We have continued to hold online gaming tournaments for the Duchenne community. This has helped people living with Duchenne connect and create support networks to improve mental health.

Duchenne UK has recruited a new Director of Research and we have been working on a new research strategy to share in Q1 2022.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Achievement and performance

Funding and research decisions

We have listed in the table below a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy.

We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

| |
|-------------------------------|
| DMD Care UK = Red |
| Basic Research = Yellow |
| Preclinical Research = Green |
| Clinical Trial Support = Blue |
| Clinical Trials = Orange |

| Project Name | Research/Institution or Company | Project Status | Total Grant Award |
|---|--|----------------|-------------------|
| Hydrotherapy Clinical Trial | Dr De Geode, Royal Preston Hospital | Started | £118,000 |
| Immunology Grant Call Award | Professor Kanneboyina Nagaraju at Binghamton, the State University of New York | Started | £1,000 |
| Biomarker Trial | Duke University | Started | £20,000 |
| Dream Chair development | Whizz Kidz | ONGOING | £50,000 |
| DMD Care UK | Newcastle University | ONGOING | £65,000 |
| Immunology Grant | University of Florida | ONGOING | £185,000 |
| Splint Trial | Newcastle University | Started | 10,0000 |
| Stem Cells | University of Minnesota | ONGOING | £140,000 |
| Vitamin B3 | Leiden University | Complete | £10,000 |
| Tackling fibrosis and muscle regeneration | Agada Biosciences | Terminated | £25,000 |
| Repurposing Drugs | Dr Olivier Dorchies University of Geneva | ONGOING | £25,000 |
| Testosterone extension | Prof Volker Straub University of Newcastle | ONGOING | £10,000 |
| Adult NMCCC | Dr Chiara Marini-Bettolo University of Newcastle | ONGOING | £10,000 |

| Project Name | Research/Institution or Company | Project Status | Total Grant Award |
|---|---|-----------------------|-------------------|
| <u>Open label extension study for Tamoxifen</u> | Dr Dirk Fischer University Children's Hospital Basel | ONGOING | £230,000 |
| <u>Taurine</u> | Dr Peter Arthur, Senior Lecturer The University of Western Australia | COMPLETE 2018-2020 | £50,000 |
| <u>Fibrosis</u> | Dr Lee Borthwich, University of Newcastle | ONGOING 2018-2019 | £10,000 |
| <u>New ways of delivering Gene Therapy</u> | EVOX Therapeutics | TERMINATED | £200,000 |
| <u>Understanding heart disease in DMD</u> | Dr John Bourke Freeman Hospital | ONGOING | £67,000 |
| <u>Investigating soy products as a treatment for DMD</u> | Prof Steve Winder University of Sheffield | COMPLETE 2018-2019 | £30,500 |
| <u>Preclinical study of the combination of tamoxifen, L-citrulline and metformin</u> | Dr Olivier Dorchies University of Geneva | ONGOING 2018-2020 | £200,000 |
| <u>Use of Elastase Inhibitors to Treat DMD</u> | Dr Addolorata Pisconti University of Liverpool | COMPLETE 2017-2018 | £36,365 |
| <u>Duchenne Clinical Research Nurse</u> | Alder Hey Children's Hospital, Liverpool | ONGOING 2018-2020 | £32,106.50 |
| <u>F2 Neuromuscular Clinical Research Doctor</u> | Alder Hey Children's Hospital, Liverpool | COMPLETE 2017-2018 | £30,513 |
| <u>ST4 Neuromuscular Clinical Research Doctor</u> | Alder Hey Children's Hospital, Liverpool | COMPLETE 2017-2019 | £127,121 |
| <u>Tamoxifen Clinical Trial</u> | Dr Dirk Fischer University Children's Hospital Basel | ONGOING | £194,996.99 |
| <u>Tamoxifen Project Manager</u> | Dr Dirk Fischer University Children's Hospital Basel | ONGOING | £97,000 |
| <u>TREAT-NMD DMD Co-Ordinator Role</u> | University of Newcastle | COMPLETE 2015-2020 | £78,832.66 |
| <u>Physiotherapist</u> | Alder Hey Children's Hospital, Liverpool | COMPLETE 2016-2018 | £45,960 |
| <u>Duchenne Clinical Trial Nurse</u> | Royal Victoria Infirmary, Newcastle | COMPLETE 2017-2018 | £22,500 |
| <u>Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy</u> | Dr Guglieri University of Newcastle | COMPLETE 2015-2020 | £35,714.30 |
| <u>Assessing the preclinical therapeutic impact of cannabidiol for DMD</u> | Dr Keith Foster The University of Reading | COMPLETE 2014-2016 | £6213.09 |
| <u>The Duchenne Forum</u> | Muscular Dystrophy Campaign | COMPLETE 2014-2017 | £55,346 |
| <u>Supporting 8 basic research projects</u> | | | |

| Project Name | Research/Institution or Company | Project Status | Total Grant Award |
|---|---------------------------------|----------------|-------------------|
| Gene therapy | Solid GT | COMPLETE | \$1,666,666.66 |
| VBP-15 | Boston, USA | 2014-2016 | |
| Phase I Clinical Trial | Reveragen BioPharma Inc, USA | COMPLETE | \$400,000 |
| DMD Heart Protection Study | Dr Spinty | 2014-2015 | |
| Phase I/2 | Alder Hey | COMPLETE | £14,000 |
| Clinical trial of HT-100 | Akashi Therapeutics | 2014-2017 | |
| | USA | COMPLETE | \$100,000 |
| Developing biomarkers for Utrophin Modulators | Summit Corporation | 2013-2015 | |
| | Oxford, UK | COMPLETE | £100,000 |

Financial review

Financial position

Results for the year are shown in the Statement of Financial Activities on page 14.

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Future plans

Our future plans

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care for patients in the UK.
- Provide education to families on research and care.
- Provide psychological support to families and patients living with Duchenne through the pathway we develop.
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Bring the Dream Chair to market.
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs

Structure, governance and management

Constitution

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 1. The trustees are appointed by the committee.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Structure, governance and management

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision-making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Statement of trustees' responsibilities


The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on 10th February 2022 and signed on its behalf by:



Mr K Radlinski - Trustee

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF JOINING JACK

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF JOINING JACK

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the directors and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related companies legislation), distributable profits legislation, pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



.....
Paul G Farrington BSc (Hons) ACA (Senior Statutory Auditor)
For and on behalf of NR Barton
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

Date: 10/02/2022

JOINING JACK

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2021

| | | 30.4.21 Unrestricted fund £ | 30.4.20 Total funds £ |
|--|--------------|--------------------------------------|--------------------------------|
| INCOME AND ENDOWMENTS FROM | Notes | | |
| Donations and legacies | 2 | 44,590 | 151,844 |
| Other trading activities | 3 | 142,423 | 217,852 |
| Investment income | 4 | <u>155</u> | <u>586</u> |
| Total | | 187,168 | 370,282 |
| EXPENDITURE ON | | | |
| Raising funds | 5 | 68,323 | 152,992 |
| Charitable activities | 6 | | |
| Funding research | | 434,323 | 335,328 |
| Other | | <u>(277,073)</u> | <u>747,312</u> |
| Total | | <u>225,573</u> | <u>1,235,632</u> |
| NET INCOME/(EXPENDITURE) | | (38,405) | (865,350) |
| RECONCILIATION OF FUNDS | | | |
| Total funds brought forward | | <u>2,993,539</u> | <u>3,858,889</u> |
| TOTAL FUNDS CARRIED FORWARD | | <u><u>2,955,134</u></u> | <u><u>2,993,539</u></u> |

The notes form part of these financial statements

JOINING JACK

BALANCE SHEET 30 APRIL 2021

| | Notes | 30.4.21 Unrestricted fund £ | 30.4.20 Total funds £ |
|--|-------|--------------------------------------|--------------------------------|
| FIXED ASSETS | | | |
| Tangible assets | 12 | 255 | 318 |
| Social investments | 13 | <u>592,260</u> | <u>315,187</u> |
| | | 592,515 | 315,505 |
| CURRENT ASSETS | | | |
| Stocks | 14 | 322 | 322 |
| Debtors | 15 | 85 | 85 |
| Cash at bank | | <u>2,367,631</u> | <u>2,686,183</u> |
| | | 2,368,038 | 2,686,590 |
| CREDITORS | | | |
| Amounts falling due within one year | 16 | (5,419) | (8,556) |
| NET CURRENT ASSETS | | <u>2,362,619</u> | <u>2,678,034</u> |
| TOTAL ASSETS LESS CURRENT LIABILITIES | | <u>2,955,134</u> | <u>2,993,539</u> |
| NET ASSETS | | <u>2,955,134</u> | <u>2,993,539</u> |
| FUNDS | 17 | | |
| Unrestricted funds | | <u>2,955,134</u> | <u>2,993,539</u> |
| TOTAL FUNDS | | <u>2,955,134</u> | <u>2,993,539</u> |

The financial statements were approved by the Board of Trustees and authorised for issue on 10 February 2022 and were signed on its behalf by:



Mr J Whitworth - Trustee

JOINING JACK

CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2021

| | Notes | 30.4.21 £ | 30.4.20 £ |
|---|-------|-------------------------|-------------------------|
| Cash flows from operating activities | | | |
| Cash generated from operations | 1 | <u>(318,706)</u> | <u>(119,869)</u> |
| Net cash used in operating activities | | <u>(41,633)</u> | <u>(119,869)</u> |
| Cash flows from investing activities | | | |
| Interest received | | 155 | 586 |
| Dividends received | | <u>-</u> | <u>256,918</u> |
| Net cash provided by investing activities | | <u>155</u> | <u>257,504</u> |
| | | <u> </u> | <u> </u> |
| Change in cash and cash equivalents in the reporting period | | <u>(318,552)</u> | <u>137,635</u> |
| Cash and cash equivalents at the beginning of the reporting period | | <u>2,686,183</u> | <u>2,548,548</u> |
| Cash and cash equivalents at the end of the reporting period | | <u><u>2,367,631</u></u> | <u><u>2,686,183</u></u> |

The notes form part of these financial statements

JOINING JACK

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2021

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

| | 30.4.21 £ | 30.4.20 £ |
|---|------------------|------------------|
| Net expenditure for the reporting period (as per the Statement of Financial Activities) | (38,405) | (865,350) |
| Adjustments for: | | |
| Depreciation charges | 64 | 80 |
| Losses/(gain) on investments | (277,073) | 1,000,816 |
| Interest received | (155) | (586) |
| Dividends received | - | (256,918) |
| Decrease in stocks | - | 8 |
| (Decrease)/increase in creditors | <u>(3,137)</u> | <u>2,081</u> |
| Net cash used in operations | <u>(318,706)</u> | <u>(119,869)</u> |

2. ANALYSIS OF CHANGES IN NET FUNDS

| | At 1.5.20 £ | Cash flow £ | At 30.4.21 £ |
|--------------|------------------|------------------|------------------|
| Net cash | | | |
| Cash at bank | <u>2,686,183</u> | <u>(318,552)</u> | <u>2,367,631</u> |
| | <u>2,686,183</u> | <u>(318,552)</u> | <u>2,367,631</u> |
| Total | <u>2,686,183</u> | <u>(318,552)</u> | <u>2,367,631</u> |

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| | |
|-----------------------|---------------------------|
| Fixtures and fittings | - 20% on reducing balance |
|-----------------------|---------------------------|

Social investments

Social investments comprise programme related investments which are measured at cost less impairment.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

2. DONATIONS AND LEGACIES

| | 30.4.21 | 30.4.20 |
|-----------|---------------|----------------|
| | £ | £ |
| Donations | <u>44,590</u> | <u>151,844</u> |

3. OTHER TRADING ACTIVITIES

| | 30.4.21 | 30.4.20 |
|--------------------|----------------|----------------|
| | £ | £ |
| Fundraising events | 142,423 | 217,672 |
| Merchandise sales | <u>-</u> | <u>180</u> |
| | <u>142,423</u> | <u>217,852</u> |

4. INVESTMENT INCOME

| | 30.4.21 | 30.4.20 |
|--------------------------|------------|------------|
| | £ | £ |
| Deposit account interest | <u>155</u> | <u>586</u> |

5. RAISING FUNDS

Raising donations and legacies

| | 30.4.21 | 30.4.20 |
|--------------------------------|---------------|---------------|
| | £ | £ |
| Staff costs | 53,725 | 51,935 |
| Rent | 2,400 | 2,400 |
| Fundraising costs | 17,762 | 5,169 |
| Travel costs | - | 3,142 |
| Postage, stationery and sundry | 864 | 1,619 |
| Computer costs | 1,986 | 1,572 |
| Depreciation | 64 | 80 |
| Government Grants | (12,197) | - |
| Support costs | <u>4,630</u> | <u>-</u> |
| | <u>69,234</u> | <u>65,917</u> |

6. CHARITABLE ACTIVITIES COSTS

| | Grant funding of activities (see note 7) £ |
|------------------|---|
| Funding research | <u>434,323</u> |

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

7. GRANTS PAYABLE

| | 30.4.21 | 30.4.20 |
|------------------|----------------|----------------|
| | £ | £ |
| Funding research | <u>434,323</u> | <u>335,328</u> |

The total grants paid to institutions during the year was as follows:

| | 30.4.21 | 30.4.20 |
|------------------------|----------------|----------------|
| | £ | £ |
| Newcastle University | - | 15,328 |
| Duchenne UK Grant Call | 434,323 | 200,000 |
| Catabasis | - | 100,000 |
| Testosterone | - | 10,000 |
| Adult Hub | - | 10,000 |
| | <u>434,323</u> | <u>335,328</u> |

8. SUPPORT COSTS

| | Governance costs |
|--------------------------------|------------------|
| | £ |
| Raising donations and legacies | <u>4,630</u> |

Support costs, included in the above, are as follows:

| | 30.4.21 | 30.4.20 |
|---|--------------------------------|------------------|
| | Raising donations and legacies | Total activities |
| | £ | £ |
| Auditors' remuneration | 4,090 | 3,414 |
| Auditors' remuneration for non audit work | 360 | - |
| Accountancy and legal fees | <u>180</u> | <u>-</u> |
| | <u>4,630</u> | <u>3,414</u> |

9. AUDITORS' REMUNERATION

| | 30.4.21 | 30.4.20 |
|--|------------|----------|
| | £ | £ |
| Fees payable to the charity's auditors for the audit of the charity's financial statements | 4,090 | 3,414 |
| Auditors' remuneration for non audit work | <u>360</u> | <u>-</u> |

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2021 nor for the year ended 30 April 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2021 nor for the year ended 30 April 2020.

11. STAFF COSTS

| | 30.4.21 | 30.4.20 |
|--------------------|---------------|---------------|
| | £ | £ |
| Wages and salaries | <u>53,725</u> | <u>51,935</u> |
| | <u>53,725</u> | <u>51,935</u> |

The average monthly number of employees during the year was as follows:

| | 30.4.21 | 30.4.20 |
|--------------------------------------|----------|----------|
| Costs of generating voluntary income | 2 | 2 |
| Research and campaigning | <u>1</u> | <u>1</u> |
| | <u>3</u> | <u>3</u> |

No employees received emoluments in excess of £60,000.

12. TANGIBLE FIXED ASSETS

| | Fixtures and fittings £ |
|---------------------------------|----------------------------------|
| COST | |
| At 1 May 2020 and 30 April 2021 | <u>1,461</u> |
| DEPRECIATION | |
| At 1 May 2020 | 1,143 |
| Charge for year | <u>63</u> |
| At 30 April 2021 | <u>1,206</u> |
| NET BOOK VALUE | |
| At 30 April 2021 | <u>255</u> |
| At 30 April 2020 | <u>318</u> |

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

13. SOCIAL INVESTMENTS

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

At 30 April 2021 the share price of SOLID Biosciences had reduced as a result of research projects led by the company being put on hold given the implications the global pandemic. As a result, the market value of the investment in DRIL as at the balance sheet date is shows a revaluation of £277,073 (2020 - £743,898 impairment) compared to the original cost of £1,073,399.

Further commentary regarding the charity's investment in DRIL is included in the financial review section of the Trustee's Report.

14. STOCKS

| | 30.4.21 | 30.4.20 |
|--------|------------|------------|
| | £ | £ |
| Stocks | <u>322</u> | <u>322</u> |

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

| | 30.4.21 | 30.4.20 |
|-----------------|-----------|-----------|
| | £ | £ |
| Gift Aid debtor | <u>85</u> | <u>85</u> |

16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

| | 30.4.21 | 30.4.20 |
|------------------------------|--------------|--------------|
| | £ | £ |
| Trade creditors | 1,999 | 2,000 |
| Taxation and social security | - | 708 |
| Other creditors | <u>3,420</u> | <u>5,848</u> |
| | <u>5,419</u> | <u>8,556</u> |

17. MOVEMENT IN FUNDS

| | At 1.5.20 | Net movement in funds | At 30.4.21 |
|--------------------|------------------|-----------------------|------------------|
| | £ | £ | £ |
| Unrestricted funds | | | |
| General fund | 2,993,539 | (38,405) | 2,955,134 |
| | <u>2,993,539</u> | <u>(38,405)</u> | <u>2,955,134</u> |
| TOTAL FUNDS | | | |
| | <u>2,993,539</u> | <u>(38,405)</u> | <u>2,955,134</u> |

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

17. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 187,168 | (225,573) | (38,405) |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>187,168</u> | <u>(225,573)</u> | <u>(38,405)</u> |

Comparatives for movement in funds

| | At 1.5.19 £ | Net movement in funds £ | At 30.4.20 £ |
|---------------------------|------------------|----------------------------------|--------------------|
| Unrestricted funds | | | |
| General fund | 3,858,889 | (865,350) | 2,993,539 |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>3,858,889</u> | <u>(865,350)</u> | <u>2,993,539</u> |

Comparative net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|----------------------------|----------------------------|---------------------------|
| Unrestricted funds | | | |
| General fund | 370,282 | (1,235,632) | (865,350) |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>370,282</u> | <u>(1,235,632)</u> | <u>(865,350)</u> |

A current year 12 months and prior year 12 months combined position is as follows:

| | At 1.5.19 £ | Net movement in funds £ | At 30.4.21 £ |
|---------------------------|------------------|----------------------------------|--------------------|
| Unrestricted funds | | | |
| General fund | 3,858,889 | (903,755) | 2,955,134 |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>3,858,889</u> | <u>(903,755)</u> | <u>2,955,134</u> |

JOINING JACK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2021**

17. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

| | Incoming resources £ | Resources expended £ | Movement in funds £ |
|---------------------------|-------------------------------------|-------------------------------------|------------------------------------|
| Unrestricted funds | | | |
| General fund | 557,450 | (1,461,205) | (903,755) |
| | <hr/> | <hr/> | <hr/> |
| TOTAL FUNDS | <u>557,450</u> | <u>(1,461,205)</u> | <u>(903,755)</u> |

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2021.

JOINING JACK

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2021

| | 30.4.21 £ | 30.4.20 £ |
|---|--------------|--------------|
| INCOME AND ENDOWMENTS | | |
| Donations and legacies | | |
| Donations | 44,590 | 151,844 |
| Other trading activities | | |
| Fundraising events | 142,423 | 217,672 |
| Merchandise sales | - | 180 |
| | 142,423 | 217,852 |
| Investment income | | |
| Deposit account interest | 155 | 586 |
| Total incoming resources | 187,168 | 370,282 |
| EXPENDITURE | | |
| Raising donations and legacies | | |
| Wages | 53,725 | 51,935 |
| Rent | 2,400 | 2,400 |
| Fundraising costs | 17,762 | 5,169 |
| Travel costs | - | 3,142 |
| Postage, stationery and sundry | 864 | 1,619 |
| Computer costs | 1,986 | 1,572 |
| Depreciation of fixtures and fittings | 64 | 80 |
| Government Grants | (12,197) | - |
| | 64,604 | 65,917 |
| Other trading activities | | |
| Cost of events | (911) | 87,075 |
| Charitable activities | | |
| Grants to institutions | 434,323 | 335,328 |
| Other | | |
| Impairment losses for intangible fixed assets | (277,073) | 743,898 |
| Support costs | | |
| Governance costs | | |
| Auditors' remuneration | 4,090 | 3,414 |
| Auditors' remuneration for non-audit work | 360 | - |
| Accountancy and legal fees | 180 | - |
| | 4,630 | 3,414 |
| Total resources expended | 225,573 | 1,235,632 |
| Net expenditure | (38,405) | (865,350) |

This page does not form part of the statutory financial statements

